BIND News 9.58 Bind Therapeutics Inc (BIND)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Bind Therapeutics Inc (BIND) 9.58 $BIND

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting
Business Wire - Mon Apr 07, 3:01PM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting. The clinical data from a completed Phase 1 study demonstrate differentiating attributes of BIND-014 administered with a weekly dosing schedule which may enable increased dose intensity and enhanced therapeutic efficacy of BIND-014. In addition, data supporting the potential utility of PSMA as a target and marker for BIND-014 patient selection were presented.

Company news for March 26, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 9:06AM CDT
Companies in the News are: CCL,BIND,MKC,WAG

BIND Therapeutics, Inc. [BIND] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Mar 25, 10:21AM CDT
What:

BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Tue Mar 25, 6:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today reported financial results for the fourth quarter and year-ended December 31, 2013.

BIND Therapeutics to Ring the NASDAQ Stock Market Opening Bell on March 26, 2014
Business Wire - Wed Mar 19, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that Company management will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on Wednesday, March 26, 2014. A live webcast will be available at https://new.livestream.com/nasdaq/live.

BIND Therapeutics to Report Fourth Quarter and Year End 2013 Financial Results and Business Developments on March 25, 2014
Business Wire - Tue Mar 18, 7:30AM CDT
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced it will report fourth quarter and year ended December 31, 2013 financial results on Tuesday, March 25, 2014. BIND's management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time, on Tuesday, March 25, 2014 to discuss the quarterly results and recent business developments.

BIND Therapeutics to Present Data at the AACR 2014 Annual Meeting
Business Wire - Wed Mar 05, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that three poster presentations including clinical data on its lead drug candidate, BIND-014 and preclinical data on its AstraZeneca collaboration based on Barasertib (AZD1152), will be presented at the upcoming American Association of Cancer Research (AACR) meeting which takes place April 5-9, 2014 in San Diego, CA.

BIND Therapeutics Promotes Key Executives: Organization Positioned for Continued Growth
Business Wire - Mon Mar 03, 3:15PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that it has structured its management team for future growth by promoting and expanding the areas of responsibility for members of its management team. Andrew Hirsch has been appointed Chief Operating Officer with expanded responsibilities, including program and alliance management and oversight of BIND's Russian operations. Andrew will continue to serve as Chief Financial Officer of the company. Jeff Hrkach, Ph.D., formerly Senior Vice President, Technology Research and Development, has been promoted to Chief Technology Officer with responsibility for the research, development and manufacturing of BIND's Accurin pipeline and research and technology development related to BIND's Medicinal Nanoengineering(R) platform.

BIND Therapeutics to Present at 26th Annual Roth Conference
Business Wire - Wed Feb 26, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the 26th Annual Roth Conference in Laguna Nigel, CA on Monday, March 10, 2014 at 11:30 a.m. PT.

BIND Therapeutics to Present at Cowen 34th Annual Healthcare Conference
Business Wire - Mon Feb 24, 8:04AM CST
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the Cowen 34th Annual Healthcare Conference in Boston on Tuesday, March 4, 2014 at 10:40 a.m. ET.

3 Biotech Stocks Rising on Big Volume
at The Street - Tue Feb 11, 5:00AM CST
Keep these biotech stocks trading on unusual volume on your radar.

Concise Analysis of the Opportunities in the International Graphene Industry
M2 - Mon Feb 03, 4:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/krkmk8/the_graphene) has announced the addition of the "Concise Analysis of the Opportunities in the International Graphene Industry" report to their offering. A decade ago when the first edition of the Nanotechnology Opportunity Report was published, there were predictions of untold riches for early investors, the replacement of all manufacturing as we know it, and the mythical trillion-dollar market. The author went against the grain by predicting that it would be hard for anyone to make money from nanomaterials, and that the real value would be in the applications. This has been borne out by the failure of even large global companies such as Mitsubishi Chemical and Bayer to make much headway with fullerenes and carbon nanotubes, and the failure of countless smaller nanomaterials producers. On the other hand companies making use of nanomaterials, Germany's Magforce Technologies and the US based BIND Therapeutics have shown what can be achieved when nanomaterials are applied to large addressable markets, in this case drug delivery. Is Graphene The New Nanotech? A similar amount of hype currently surrounds graphene, with wild predictions of applications ranging from microelectronics to water treatment. This report examines these claims and taking the rational approach for which the author is known, considers how valid these are and evaluates the chances of success. The author also looks in detail at the graphene producers. Graphene comes in a wide range of forms, each with its own particular set of addressable applications. No one producer covers all applications and many are destined to be niche players. As with nanomaterials, many companies currently producing graphene are destined to burn brightly and then be unceremoniously snuffed out when scale up or access to applications fails to materialise. Key Topics Covered: Introduction A Brief History of Carbon Nanomaterials Can Graphene Succeed Where Fullerenes Failed? Types of Graphene Large-Scale Production Applications of Graphene The Graphene Opportunity Advanced Materials Structural Composites Microelectronics Key Applications Photonics & Optoelectronics For more information visit http://www.researchandmarkets.com/research/kr...e_graphene

BIND Therapeutics to Present at February Healthcare Conferences
Business Wire - Tue Jan 28, 7:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that Scott Minick, BIND's President and CEO, is scheduled to present at the following healthcare conferences during February 2014:

Nasdaq stocks posting largest percentage decreases
AP - Wed Jan 08, 12:32PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

Why BIND Therapeutics Inc. Shares Soured
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 08, 11:54AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of BIND Therapeutics , a clinical-stage...

BIND Therapeutics Announces Departure of Chief Medical Officer
Business Wire - Tue Jan 07, 3:00PM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced that Greg Berk, M.D., Chief Medical Officer, will be leaving BIND to pursue another opportunity. Dr. Berk will serve as an advisor to BIND after his departure.

BIND Therapeutics included in Russell Indices
M2 - Mon Dec 23, 3:34AM CST
BIND Therapeutics Inc (Nasdaq:BIND), a clinical-stage nanomedicine platform company, announced on Friday its addition as a member of the Russell 2000, Russell 3000, Russell Global and Russell Microcap Indices at the close of market on 20 December 2013, as Russell Investments reconstitutes its comprehensive family of global indices.

BIND Therapeutics to be Added to Russell Indexes on December 20, 2013
Business Wire - Fri Dec 20, 6:30AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), announced today that it will be added as a member of the Russell 2000(R), Russell 3000(R), Russell Global and Russell Microcap Indexes at the close of market today, December 20, 2013, as Russell Investments reconstitutes its comprehensive family of global indexes.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 67

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Eight O'Clock Adds Blonde Roast Pods to Its Lineup

Updated Category News Views 149

A lighter cup of coffee just became Eight O'Clock Coffee's newest swing at the single-serve shelf. On Nov. 19, 2026, the company said it introduced Blonde Roast K-Cup pods, a bright and smooth option aimed at drinkers who prefer a lighter roast. The product is available through Keurig.com and Amazon. That is the whole announcement, and frankly it is better to keep it that...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 149

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading
PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 110

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 156

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 76

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 31

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 190

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading

Top 5 Most Recently Viewed Articles

Hexagon Agility Nets Record $100M Order from Certarus

Updated Category News Views 79

Hexagon Agility and Certarus: A Major Deal Secured There ain't nothing like landing a big fish in the business world, and Hexagon Agility just hooked a whopper. This major player in clean fuel solutions secured an order from Certarus worth a hefty $100 million. For those who keep tabs, that's Hexagon's largest order for Mobile Pipeline® modules to date, and it's all...

Continue Reading
Performance Food Group Co's Earnings: What to Expect

Updated Category News Views 111

Preparing for Performance Food Group Co's Earnings Report Performance Food Group Co PFGC is on the verge of releasing its latest quarterly earnings report. Investors are keen to know what to anticipate ahead of this significant announcement. Expectations for Earnings Performance Analysts anticipate that Performance Food Group Co will report an earnings per share (EPS) of...

Continue Reading
Innovative Collaboration Transforms Healthcare for Incarcerated Patients

Updated Category News Views 360

Innovative Partnership Shaping Correctional Healthcare Armor Health is embarking on a transformative journey in correctional healthcare through an exciting partnership with Antidote-AI, set to significantly enhance the services provided to incarcerated individuals. This collaboration brings advanced artificial intelligence (AI) capabilities to the forefront of a critical...

Continue Reading
Celebrating Innovation: A Journey Through 17 Years of Left Field Labs

Updated Category News Views 405

Left Field Labs Marks 17 Years of Innovation and Growth Left Field Labs, a creative technology agency within Stagwell (NASDAQ: STGW), celebrates its 17th anniversary with impressive revenue growth and a diverse global client base. This celebration highlights its commitment to delivering transformative digital experiences using advanced AI technologies. Transformative...

Continue Reading
Leadership Changes at Humphreys Capital Pave New Pathway

Updated Category News Views 465

Humphreys Capital's Leadership Transition Overview Humphreys Capital, a prominent institutional investment manager, has announced significant changes in its leadership team. This transition includes the appointment of Grant Humphreys as Chairman of the Board of Directors, succeeding his father, Kirk Humphreys, who will continue his involvement as Chairman Emeritus. Blair...

Continue Reading